LTR Pharma Limited Share Price

LTP

AU0000305294

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:52 21/06/2024 am IST			5-day change	1st Jan Change
0.665 ^AUD	-7.64%		-13.64%	+92.75%

07/06	LTR Pharma's Nasal Spray Treatment for Erectile Dysfunction Obtains Positive Early Results in Trial; Shares Surge 33%	MT
06/06	LTR Pharma Requests for Voluntary Suspension Pending Clinical Study Results	MT

Latest news about LTR Pharma Limited

LTR Pharma's Nasal Spray Treatment for Erectile Dysfunction Obtains Positive Early Results in Trial; Shares Surge 33%	07/06	MT
LTR Pharma Requests for Voluntary Suspension Pending Clinical Study Results	06/06	MT
LTR Pharma Concludes Final Dose in SPONTAN Study	25/03	MT
LTR Pharma Doses First SPONTAN Patients	19/03	MT
LTR Pharma Launches Patient Recruitment for Erectile Dysfunction Drug Clinical Study	19/02	MT
LTR Pharma Receives Manufacturing Validation for SPONTAN Bioequivalence Study; Shares Down 3%	06/02	MT
LTR Pharma to Conduct Bioequivalence Clinical Trial for Spontan in Q1 2024	19/12	MT
LTR Pharma Limited Receives Approval from the Bellberry Human Research Ethics Committee for Bioequivalence Clinical Trial	18/12	CI
LTR Pharma to Start Trading on Australian Bourse Following AU$7 Million IPO	08/12	MT
LTR Pharma Limited has completed an IPO in the amount of AUD 7 million.	07/12	CI

More news

Highs and lows

1 week

0.67

0.83

1 month

0.45

1.05

Current year

0.24

1.05

1 year

0.24

1.05

3 years

0.24

1.05

5 years

0.24

1.05

10 years

0.24

1.05

More quotes

LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on holistically improving menâs health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LTR PHARMA LIMITED	+92.75%	61.49M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-16.19%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
INSMED INCORPORATED	+119.39%	10.96B